Wall Street didn't seem much enthused about Idera Pharmaceuticals Inc.'s data from the ongoing phase II trial called Illuminate-204 testing the intratumorally delivered Toll-like receptor 9 (TLR9) agonist tilsotolimod in combination with Yervoy (ipilimumab, Bristol-Myers Squibb Co.) against melanoma, but lead investigator Adi Diab from MD Anderson Cancer Center said that "to see such a durable response for these patients really creates hope. This is clearly an effective combination."